These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33950229)

  • 21. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
    Choy EHS; Miceli-Richard C; González-Gay MA; Sinigaglia L; Schlichting DE; Meszaros G; de la Torre I; Schulze-Koops H
    Clin Exp Rheumatol; 2019; 37(4):694-704. PubMed ID: 30767864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.
    Murakami K; Kobayashi Y; Uehara S; Suzuki T; Koide M; Yamashita T; Nakamura M; Takahashi N; Kato H; Udagawa N; Nakamura Y
    PLoS One; 2017; 12(7):e0181126. PubMed ID: 28708884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
    McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
    Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication.
    Reiterer G; Yen A
    Cancer Res; 2006 Sep; 66(18):9083-9. PubMed ID: 16982750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
    Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
    Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK inhibitors for rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
    Tran NV; Nguyen LTA; Lim KW; Phan AT
    Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
    Taylor PC
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
    Dai Z; Chen J; Chang Y; Christiano AM
    JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
    Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
    J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.
    Meyer DM; Jesson MI; Li X; Elrick MM; Funckes-Shippy CL; Warner JD; Gross CJ; Dowty ME; Ramaiah SK; Hirsch JL; Saabye MJ; Barks JL; Kishore N; Morris DL
    J Inflamm (Lond); 2010 Aug; 7():41. PubMed ID: 20701804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK: Not Just Another Kinase.
    Agashe RP; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
    Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
    Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
    Orsolini G; Bertoldi I; Rossini M
    Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.
    Xiang J; Wang Y; Wang W; Yu J; Zheng L; Hong Y; Shi L; Zhang C; Chen N; Xu J; Gong X; Zhang Z; Cui H; Zhou Q; Zhang D; Liu Y; Ke Y; Shen J; Xia G; Bai X
    Bioorg Chem; 2023 Nov; 140():106765. PubMed ID: 37582330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes.
    Beadling C; Guschin D; Witthuhn BA; Ziemiecki A; Ihle JN; Kerr IM; Cantrell DA
    EMBO J; 1994 Dec; 13(23):5605-15. PubMed ID: 7988557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.